Tandem Mobi Wins Tubeless Clearance for Seven Days

Tandem Diabetes Care has won Food and Drug Administration clearance for a tubeless version of its Mobi insulin pump. The company announced the clearance on November 13, 2026, and it calls Mobi the world's first and only tubeless automated insulin delivery system rated for up to seven days of wear. The clearance came through the 510(k) pathway on November 12.

The seven-day figure belongs to the infusion set, not to the whole system. The new tubeless cartridge is cleared for three days of use, the same limit the current Mobi cartridge already carries. A user who wears a set for a full week will still handle a cartridge change partway through, and Tandem hasn't explained how that swap works while the set stays on the body.

The flexibility is real, though. Mobi now offers tubed and tubeless wear on the same pump, and Tandem says it's the only pump that lets users choose between the two. Customers whose Mobi pump is in warranty won't need a new pump to go tubeless. The pump runs Tandem's Control-IQ+ software, which predicts glucose 30 minutes ahead and adjusts insulin every five minutes.

The commercial path is narrow at the start. Tandem plans a full United States launch in the first half of 2027, later than the 2026 launch it had aimed for, and tubeless supplies will sell only through the pharmacy channel for customers with pharmacy benefits. That channel decides who can actually get the seven-day set, whatever the clearance says.

The clearance lands in a hard month for the same product line. Tandem is also correcting more than 80,000 Mobi pumps after false occlusion alarms suspended insulin delivery for some users. The company had received 230 reports of adverse events that required medical help or hospitalization as of October 29, and no deaths. The recall and the clearance cover different parts of the system, but a buyer will read them together.

For people who wear a pump every day, seven days without a set change is a genuine gain, and three days on the cartridge is the honest limit inside it. The launch in the first half of 2027 will show whether the pharmacy-only route puts that gain within reach or behind another counter.